Medical Condition News

RSS

New endoscopic OCT system enables 3-D imaging of esophagus, colon cancers

Researchers at the Massachusetts Institute of Technology (MIT) have developed a new imaging system that enables high-speed, three-dimensional (3-D) imaging of microscopic pre-cancerous changes in the esophagus or colon.

2 Aug 2011

FDA clears Derma Sciences' MEDIHONEY Hydrogel Wound and Burn Dressing

Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today announced it has received U.S. Food and Drug Administration 510(k) clearance for its patented MEDIHONEY Hydrogel Wound and Burn Dressing with Leptospermum honey.

2 Aug 2011

Can-Fite commences CF101 phase 2/3 trial for treatment of Psoriasis

Can-Fite BioPharma Ltd, a biotechnology company developing small molecule drugs for the treatment of inflammatory, ophthalmic, and liver diseases, traded on the Tel Aviv Stock Exchange announced today that it has commenced patient enrolment in a phase 2/3 clinical trial of CF101 for the treatment of Psoriasis.

2 Aug 2011

Spiritual retreat can help heart patients return to psycho-spiritual well-being

Attending a non-denominational spiritual retreat can help patients with severe heart trouble feel less depressed and more hopeful about the future, a University of Michigan Health System study has found.

1 Aug 2011

Mathematical model predicts progress of tumors from early stages to metastasis

Researchers from the University of Miami (UM) and the University of Heidelberg in Germany have developed a mathematical model to understand and predict the progress of a tumor, from its early stages to metastasis, in hopes of creating highly personalized treatment strategies for patients who have cancer. The findings are published in Nature's new online journal Scientific Reports.

1 Aug 2011

Femta files IND with FDA for FM101 monoclonal antibody against RA

Femta Pharmaceuticals announced today that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate a clinical development program for FM101, a high-affinity, humanized monoclonal antibody against Interleukin-6 (IL-6), in patients with rheumatoid arthritis (RA).

1 Aug 2011

Prohibitive costs prevent elders from sticking to prescribed medication

As many as one in ten elderly people in the US, registered with Medicare, do not stick to their prescribed medication because it is too expensive, according to Dr. Larissa Nekhlyudov and colleagues from Harvard Medical School.

1 Aug 2011

HT, B.Braun partner to launch Adenocaine Hiberplegia syringe pump delivery system

Hibernation Therapeutics USA, LLC has partnered with B. Braun Medical Inc. to introduce an innovative, low-cost syringe pump delivery system for the administration of its patented Adenocaine Hiberplegia solution, the world's first non-depolarizing cardioplegia.

From B. Braun Melsungen AG 1 Aug 2011

FDA approves Covidien's morphine sulfate oral solution for chronic pain in opioid-tolerant patients

Covidien, a leading global provider of healthcare products, today announced that the U.S. Food and Drug Administration (FDA) recently granted approval to the company's Mallinckrodt business for morphine sulfate oral solution, used to relieve moderate to severe acute and chronic pain in opioid-tolerant patients. The solution will be available as a generic in 100 milligrams per 5 mL (20 milligrams per 1 mL).

1 Aug 2011

Mobile health software effectively helps manage diabetes

An interactive computer software program appears to be effective in helping patients manage their Type 2 diabetes using their mobile phones, according to a new study by University of Maryland School of Medicine researchers.

1 Aug 2011

Positive results from Alnylam's ALN-VSP Phase I trial for liver cancer

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has completed its Phase I study with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement.

1 Aug 2011

Merck submits ridaforolimus MAA with EMA for treatment of metastatic soft-tissue, bone sarcomas

ARIAD Pharmaceuticals, Inc. today announced that its ridaforolimus partner, Merck, has submitted a marketing authorization application (MAA) for ridaforolimus with the European Medicines Agency.

1 Aug 2011

Artificial nanoparticles have direct effect on heart rate and rhythm

Artificial nanoparticles are becoming increasingly pervasive in modern life. However, their influence on our health and the mechanisms by which they affect the human body remain largely shrouded in mystery.

1 Aug 2011

Stealth presents Bendavia at AHA's Cardiovascular Scientific Sessions

Stealth Peptides Inc. (Stealth), a privately held biopharmaceutical company developing innovative mitochondrial therapies for diseases with unmet medical needs, presented its lead clinical candidate, Bendavia, during the 2011 American Heart Association's (AHA) Cardiovascular Scientific Sessions.

1 Aug 2011

Affymetrix to commercialize four Axiom genotyping arrays for the major populations

Affymetrix, Inc. today announced plans to commercialize four Axiom population-optimized arrays used to analyze 100,000 samples collected from volunteers in one of the nation's largest and most diverse genomics projects funded by the National Institutes of Health.

1 Aug 2011

Tips for obtaining life insurance after heart attack

Life Quotes, Inc. wants heart attack survivors to know that, while it may be tough to get a life insurance policy, it's not impossible. Heart disease is the #1 cause of death in America and many survivors are unaware of the life insurance options that may be open to them.

1 Aug 2011